- In April 2023, Becton, Dickinson and Company (BD) announced the commercial launch of its BD Libertas Wearable Injector for subcutaneous delivery of biologics. Designed for high-viscosity and high-volume drugs, the device supports patient self-administration outside clinical settings, aligning with the global shift toward home-based care. This development underscores BD’s commitment to advancing patient-friendly biologic delivery technologies and enhancing treatment adherence for chronic diseases
- In March 2023, Ypsomed AG entered into a strategic collaboration with Novo Nordisk to develop a next-generation autoinjector platform tailored for self-injection of large-molecule biologics. This partnership aims to combine Ypsomed’s drug delivery expertise with Novo Nordisk’s biologic portfolio to improve patient outcomes and convenience. The initiative reflects growing demand for customizable, high-performance autoinjectors across therapeutic areas
- In March 2023, SHL Medical launched the Maggie autoinjector, a modular platform designed to accommodate a variety of biologic formulations, including high-volume and high-viscosity drugs. With an emphasis on patient-centric design and connectivity capabilities, Maggie® enhances ease of use and data tracking, enabling better patient engagement and remote monitoring. This innovation highlights SHL’s focus on versatile delivery solutions that support complex therapies
- In February 2023, Nemera introduced its Symbioze platform, a smart autoinjector featuring digital connectivity to support adherence monitoring and personalized treatment. Symbioze is designed for biologic drug delivery and offers real-time data sharing between patients and healthcare providers. This development reinforces Nemera’s commitment to digital health integration and patient-centered care in chronic disease management
- In January 2023, West Pharmaceutical Services, Inc. expanded its collaboration with leading biotech companies to co-develop next-generation autoinjectors for emerging biologics. These efforts focus on enhancing the reliability and ergonomic performance of delivery devices, particularly for self-administered therapies. The company’s increased investment in device innovation highlights the strategic importance of biologic delivery systems in advancing global health outcomes
